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Molecular imaging of atherosclerosis: spotlight 
on Raman spectroscopy and surface-enhanced 
Raman scattering
Neil MacRitchie,1,2 Gianluca Grassia,1 Jonathan Noonan,1,2 Paul Garside,1 
Duncan Graham,3 Pasquale Mafia1,2,4,5
AbstRAct
To accurately predict atherosclerotic plaque progression, 
a detailed phenotype of the lesion at the molecular level 
is required. Here, we assess the respective merits and 
limitations of molecular imaging tools. Clinical imaging 
includes contrast-enhanced ultrasound, an inexpensive 
and non-toxic technique but with poor sensitivity. CT 
beneits from high spatial resolution but poor sensitivity 
coupled with an increasing radiation burden that limits 
multiplexing. Despite high sensitivity, positron emission 
tomography and single-photon emission tomography 
have disadvantages when applied to multiplex molecular 
imaging due to poor spatial resolution, signal cross 
talk and increasing radiation dose. In contrast, MRI is 
non-toxic, displays good spatial resolution but poor 
sensitivity. Preclinical techniques include near-infrared 
luorescence (NIRF), which provides good spatial 
resolution and sensitivity; however, multiplexing with 
NIRF is limited, due to photobleaching and spectral 
overlap. Fourier transform infrared spectroscopy and 
Raman spectroscopy are label-free techniques that 
detect molecules based on the vibrations of chemical 
bonds. Both techniques offer fast acquisition times with 
Raman showing superior spatial resolution. Raman 
signals are inherently weak; however, leading to the 
development of surface-enhanced Raman spectroscopy 
(SERS) that offers greatly increased sensitivity due to 
using metallic nanoparticles that can be functionalised 
with biomolecules targeted against plaque ligands while 
offering high multiplexing potential. This asset combined 
with high spatial resolution makes SERS an exciting 
prospect as a diagnostic tool. The ongoing reinements 
of SERS technologies such as deep tissue imaging and 
portable systems making SERS a realistic prospect for 
translation to the clinic.
IntRoductIon
Atherosclerosis is a complex multifactorial 
pathology that progresses over many decades. 
Immune-inflammatory responses play key roles 
in all phases of the pathology and inflammation 
contributes to plaque rupture resulting in clinical 
manifestations such as myocardial infarction (MI) 
and stroke.1 The goal of contemporary researchers 
is to develop tools useful for the early diagnosis 
and accurate classification of those plaques which 
are stable and unlikely to be of immediate concern 
from those displaying a vulnerable phenotype and 
prone to rupture-thrombosis events.
Multiple imaging techniques are available for 
both invasive and non-invasive imaging of the 
vasculature. These include contrast-enhanced 
ultrasound (CEUS), CT, MRI, positron emission 
tomography (PET), single-photon emission tomog-
raphy (SPECT), near-infrared fluorescence (NIRF) 
microscopy and vibrational spectroscopy. MRI, 
CT and PET/SPECT are already in clinical use for 
diagnosing and monitoring atherosclerosis and 
can provide structural information such as quan-
tifying stenosis and plaque size/location. In some 
instances, invasive imaging using intra-arterial 
probes employing one of the above modalities can 
reveal basic morphological information on plaque 
composition, yet there remains an urgent unmet 
requirement for non-invasive imaging tools that can 
provide information beyond the anatomic and func-
tional level that are able to interrogate the cellular 
and molecular pathways driving local inflammatory 
responses that promote plaque vulnerability.
Molecular imaging moves beyond anatomic and 
morphological detail to the level of cellular and 
molecular events. Activated endothelium offers 
a number of potential imaging targets, including 
adhesion molecules promoting leucocyte binding 
and transmigration into subendothelial locations. 
The complex inflammatory environment of a 
developing atherosclerotic plaque offers additional 
targets such as scavenger receptors present on 
macrophages/foam cells, and plaque destabilising 
proteases and peroxidases. True molecular imaging 
requires a targeting ligand (eg, antibodies, frag-
ment antigen-binding (FAB), peptides, aptamers) 
to specific molecules/cells which are conjugated 
to a detection agent compatible with the imaging 
tool of choice, eg, microbubbles (CEUS), iodinated 
compounds (CT), radionucleotides (PET/SPECT), 
magnetic/superparamagnetic compounds (MRI) or 
fluorochromes (fluorescence imaging). Vibrational 
spectroscopy, such as Raman spectroscopy, offers 
the advantage of not requiring external imaging 
tracers owing to direct detection of endogenous 
biological molecules; however, Raman spectroscopy 
employing exogenous targeted nanoparticles (NPs) 
(surface-enhanced Raman spectroscopy (SERS)) 
results in an imaging capability with remarkably 
increased sensitivity and ability to simultaneously 
detect multiple analytes (multiplexing), which 
may improve diagnostic specificity. Advantages 
and limitations of the described techniques are 
summarised in table 1.
In this review, we will highlight recent advances 
in molecular imaging and their application in iden-
tifying vascular inflammation, with a particular 
focus on the potentialities of Raman and SERS.
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contRAst-enhAnced ultRAsound
Ultrasound-based molecular imaging relies on CEUS, which 
employs the use of microbubbles as a vascular wall targeting 
agent. Signals are generated through vibration/oscillation or 
release of free gas when the microbubbles are exposed to sonic 
energy. Kaufmann et al2 using microbubbles targeted to vascular 
cell adhesion molecule 1 (VCAM-1) and p-selectin demonstrated 
the feasibility of CEUS to detect endothelial vascular changes 
that preceded early lesion formation in mice, offering the possi-
bility that CEUS could be in future used as an early screening 
tool for potential atherosclerosis development.
coMputed toMogRAphy
CT possesses relatively good temporal and spatial resolution 
which can further be improved on by multidetector spiral 
computed tomography and the concomitant use of iodinated 
contrast agents. This approach allowed the non-invasive iden-
tification of plaque location and size3 and the gross phenotypic 
classification of plaques as calcified, hypoechoic (soft) or hyper-
echoic (collagen-rich fibrous) with results correlating with those 
obtained by intracoronary ultrasound.4 Moreover, by employing 
multicolour (or spectral) CT, it is possible to distinguish between 
several composites including tissue calcium deposits and gold-la-
belled and iodine-labelled contrast agents allowing simultaneous 
imaging of multiple plaque components.5
As the current technology stands, clinical use of CT for cellular 
and molecular imaging of atherosclerosis may be restricted to 
the narrow use of identifying plaque mineral composition and 
cellular density. As with anatomic CT imaging, use in this area 
will be subject to careful review of the radioactive burden asso-
ciated with CT X-ray exposure, especially in the context of 
repeated scans. To date, the low sensitivity of CT contrast agents 
combined with spatial resolution inadequate to detect vulner-
able plaque components6 precludes its use for detailed molecular 
imaging of atherosclerotic plaques.
posItRon eMIssIon toMogRAphy/sIngle-photon 
eMIssIon toMogRAphy
PET and SPECT are widespread imaging tools that rely on the 
administration of radionucleotides and subsequent detection 
of J-rays to construct three-dimensional images of biological 
tissue forming the cornerstone of nuclear imaging. PET/SPECT 
are attractive options for molecular imaging owing to their 
non-invasive nature and high sensitivity. Furthermore, the high 
sensitivity of nuclear imaging is frequently combined with CT 
or MRI, tools with superior spatial resolution to form hybrid 
imaging systems such as PET/CT, SPECT/CT and PET/MRI.7
[18F]-Fluorodeoxyglucose (FDG) is a glucose analogue radio-
tracer commonly used in PET and uptake by tissues correlates 
table 1 Summary of non-invasive imaging modalities for use in atherosclerosis
technique Resolution scan time depth strengths limitations clinical use
CE-ultrasound 50 µM Seconds–
minutes
Several cms Low cost, no radiation, high speed and 
sequential imaging, amenable to bedside 
testing
Poor sensitivity and signal-to-noise ratio 
make molecular imaging challenging, 
lack of vascular penetration conines 
information to endothelial surface
Plaque morphology, 
thrombus and 
ulceration detection, 
stenosis severity
CT 50 µM Minutes Body-wide Relatively good spatial resolution Low sensitivity, radiation exposure,
signal cross talk between different 
tissue compartments
Plaque size, 
morphology, gross 
composition
PET/
SPECT
1–5 mm Minutes Body-wide High sensitivity Poor spatial resolution, radiation 
exposure, requires CT integration for 
anatomical analysis/quantiication, 
limited multiplex potential due to signal 
cross talk and increasing radiation dose
Plaque inlammatory 
burden
MRI 10 µM–1 mm Minutes–
hours
Body-wide Good spatial resolution, high soft tissue 
contrast, low toxicity imaging agents
Poor sensitivity, long imaging times 
often required, poor signal-to-noise 
ratio
Plaque inlammatory 
burden, morphology 
and stenosis severity
NIRF 1 µM–1 mm Minutes Several cms Good spatial resolution and sensitivity, 
relatively low cost, no radiation, moderate 
multiplexing capability
Requires hybrid technologies for higher 
resolution imaging, photobleaching of 
luorophores limits depth to supericial 
structures, relatively broad emission 
spectrum limits multiplexing, potential 
toxicity of imaging agents
None yet
FTIR 5–12 µM Seconds–
minutes
<1 cm Label-free analysis, fast imaging times, broad 
classiication of tissue morphology
Relatively low spatial resolution 
compared with Raman. Unable to 
discriminate closely related molecular 
structures
None yet
Raman <1 µM Seconds–
minutes
Several mms Label-free analysis, high spatial resolution, 
highly detailed classiication of tissue 
morphology
Low sensitivity can prolong imaging 
times, poor signal-to-noise in 
some tissues, can require complex 
chemometric analysis to separate 
analytes
None yet
SERS <100 nm Seconds Several cms High sensitivity, low toxicity of gold 
nanoparticles, fast imaging times, no 
photobleaching, can use a broad spectrum 
of existing Raman dyes, deep tissue imaging 
possible with SESORS, strong multiplexing 
capacity, portable hand-held systems now 
available
Spectra are sensitive to changes 
in nanoparticle orientation and 
interference from adjacent structures, 
complex statistical algorithms will 
be required for separation and 
quantiication of multiplexed spectra
None yet
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with metabolic activity. Combined PET/CT imaging has shown 
that FDG accumulates more in symptomatic lesions than asymp-
tomatic sites of stenosis, particularly in macrophage-rich regions.8 
Since FDG is not specifically targeted to molecular events within 
the plaque, to try to improve the specificity of PET for vascular 
inflammation, new targeting ligands have been assessed in 
animal models. A VCAM-1 targeting peptide labelled with an 
18-fluorine radiotracer was found to accumulate in the aortic 
root of atherosclerotic but not wild-type mice, being localised 
primarily to plaque endothelial cells.9 SPECT has also been used 
for in vivo imaging employing the common SPECT tracer tech-
netium-99 bound to VCAM-1-targeted ligands.10 Dual-nucleo-
tide micro-SPECT/CT imaging with a dual-head micro-SPECT 
scanner has been employed to assess the integration of distinct 
biological processes within the plaque, specifically matrix metal-
loproteinase activity and apoptosis11; however, issues of cross-
talk between radionucleotide tracers are a complication in PET/
SPECT multitarget imaging as is the enhanced toxicity risk of 
using agents producing multiple ionising radiation.
MAgnetIc ResonAnce IMAgIng
MRI is perhaps the most studied tool to date for molecular 
imaging in atherosclerosis, owing to excellent spatial and 
temporal resolution without requiring the administration of 
ionising radioactive nucleotides.
To overcome the major weakness of MRI (poor sensitivity), 
the use of paramagnetic agents such as gadolinium (Gd) chelates 
and superparamagnetic (iron oxide microparticles and nanopar-
ticles) contrast agents have been employed to non-invasively 
image arterial diseases. MRI molecular imaging of atheroscle-
rosis primarily employs ultrasmall paramagnetic iron oxide parti-
cles (USPIOs; 1050 nm in diameter). The properties of USPIOs 
allow extravasation into vascular tissues enabling potential anal-
ysis of atherosclerotic lesions. This approach has been used as 
a tool for measuring plaque macrophage burden through MRI 
signal loss following phagocytic uptake of USPIOs in rabbits12 
and in humans where MRI signal intensity correlated with 
macrophage-rich vulnerable plaques.13 Technical issues associ-
ated with vessel wall imaging using USPIOs include low signal-
to-noise ratio, poor specificity associated with the ability to 
clearly discriminate signal between anatomical locations, lengthy 
imaging times and the difficulty in standardising conditions 
between scans.12 Passive targeting of USPIOs shares the limita-
tions of FDG used in PET in not being able to detect and define 
the molecular processes governing plaque progression. A more 
direct approach involved the use of peptides targeted against 
VCAM-1 conjugated to USPIOs which are taken up by inflamed 
endothelium in addition to macrophages and vascular smooth 
muscle cells, allowing the detection of fatty-streak lesions in 
juvenile hyperlipidemic apolipoprotein E (apoE)-/- mice offering 
the potential for early intervention and monitoring.14
The use of microparticles of iron oxide (MPIO) offers several 
advantages over USPIOs. Their larger size (0.98 µm) confines 
their location to endothelial surfaces, preventing cellular uptake 
and potential consequences of cellular toxicity and loss of molec-
ular specificity. Furthermore, the greater iron payload carried by 
MIOPs improves signal detection. These attributes coupled with 
rapid clearance from the circulation can allow early imaging 
of vascular inflammation with a high degree of specificity.15 
One notable development is dual-antibody conjugated MPIOs 
targeted to p-selectin and VCAM-1, which display synergistically 
enhanced binding to plaque areas in the aortic root of apoE-/- 
mice.16 Although the MPIOs employed in basic research studies 
precludes clinical use, the multitargeting of ligands will be a key 
feature in improving diagnostics for the accurate assessment of 
local inflammatory processes.
FluoRescence IMAgIng
Fluorescence imaging is an optical imaging technique that 
detects the emission spectra from fluorescent probes excited by a 
light source. As with other imaging modalities, probes are either 
passively or actively targeted to a biological molecule or tissue 
of interest or can act as smart probes that are activated at the 
target site, for example, enzymatic conversion from a non-flu-
orescent substrate to a fluorescent product allowing functional 
read outs of local enzyme activity.17 Preclinical fluorescent 
imaging uses the near-infrared spectrum (wavelengths between 
650 and 1000 nm) and is thus referred to as near-infrared fluo-
rescence (NIRF) imaging. The advantages of imaging at these 
wavelengths is the lack of photonic absorbance from biological 
components allowing greater depth of imaging, and increased 
signal-to-noise ratio and hence specificity.18 Fluorophores are 
typically either proteins (eg, green fluorescent protein), small 
molecules or quantum dots (QDs). NIRF has been used to target 
markers of vulnerable plaques such as oxidised low-density 
lipoprotein-targeted fluorochrome-labelled antibodies19 and 
plaque destabilising proteases. Enzymatic targeting using enzyme 
substrates which fluoresce on proteolytic cleavage by a plaque 
containing protease have been employed ex vivo20 and in vivo in 
apoE-/- mice.21 More recently, near-infrared autofluorescence has 
been proposed for the identification of intraplaque haemorrhage 
as a marker of high-risk atherosclerotic lesions in both mice and 
humans.22
The wide optical imaging window available for NIRF imaging 
allows the use of multiple probes to be assessed in a single system 
owing to fluorochromes emitting in distinct spectral regions; 
however, the difficulty in resolving such spectra often requires 
multiple excitation wavelengths for optimal signal discrimina-
tion.23 QDs are still constrained by relatively broad emission 
peaks making quantification of multiple low-level analytes prob-
lematic. Limiting factors restricting clinical use to date, include 
toxicity24 and loss of fluorescent signal.
VIbRAtIonAl spectRoscopy
Vibrational spectroscopy mainly encompasses two techniques: 
infrared (IR) and Raman spectroscopies, which create molecu-
larly specific spectra based on the vibrational energies of chem-
ical bonds.
Fourier transform infrared spectroscopy
FTIR, the most refined modern form of IR spectroscopy gains 
information from the vibration of molecular bonds caused by 
absorbance of light; requiring no external labelling method. 
The ability to detect chemically specific IR spectra over a wide 
wavelength window allows FTIR to detect multiple classes of 
biological molecules. FTIR is especially useful for differentiating 
lipids and proteins and these have been the main focus of FTIR 
research in cardiovascular studies to date.
FTIR has been employed to map the distribution of collagen 
I, collagen III and elastin in the fibrous cap region of human 
atheroma samples postmortem25 and the distribution of lipids, 
which can be used to map the location and morphology of 
plaques.26 Since the relative ratios of different lipid species 
within a plaque is also an indicator of the stage of the plaque, 
information discerned from FTIR could aid in determining the 
severity of a developing atheroma. At present, FTIR can discern 
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compositional changes and aid in identifying unknown mole-
cules in a tissue sample, although with relatively low spatial 
resolution in this regard. FTIR was found to be inferior to histo-
logical staining for quantifying lipid progression in advanced 
human atheroma27 and is outperformed by Raman spectroscopy 
in the detailed characterisation of plaque composition.28
RAMAn spectRoscopy
Like FTIR, Raman spectroscopy has been used to map the 
detailed composition of atherosclerotic plaques but improves on 
FTIR in terms of both spatial and spectral resolution.29 Impor-
tantly, stimulated Raman scattering under electronic prereso-
nance conditions has recently been used to image up to 24 target 
molecules inside living cells, demonstrating the extensive multi-
plex capabilities of this technique.30 The potential of Raman 
spectroscopy to provide detailed information on plaque compo-
sition at micron and submicron resolutions has been examined in 
multiple studies summarised in table 2.28 29 3142
Raman spectroscopy is a particularly attractive molecular 
imaging tool for interrogation of atherosclerotic plaques and 
potential diagnostic agent due to its ability to non-destructively 
acquire biochemical data on the processes that drive plaque 
development. Although the non-invasive nature of Raman is an 
important advantage of the technique, the main disadvantage 
pertains to its low sensitivity due to the weakness of the Raman 
scattering effect leading to long imaging times and an inability to 
discriminate low-level target molecules from background noise. 
Furthermore, many biological molecules are spectrally similar 
requiring complex chemometric analysis to separate signals of 
interest.
suRFAce-enhAnced RAMAn spectRoscopy
The shortcomings associated with Raman spectroscopy have led 
to the development of SERS, a highly sensitive advancement of 
conventional Raman spectroscopy. The enhancement of Raman 
signal is achieved when a molecule is adsorbed onto or in close 
proximity to a metal surface and is dependent on the nature of 
metal surface, the excitation frequency used, the attachment 
of the molecule to the surface and also the nature of the mole-
cule itself.43 Silver and gold provide excellent surface enhance-
ment and can be used in a variety of physical formats including 
biocompatible NPs. Silver or gold NPs can be generated for use 
in vivo, functionalised with targeting molecules such as anti-
bodies and tuned to work across a wide range of wavelengths 
from the visible to the near IR. This has given rise to a number 
of different applications of SERS in various scenarios including 
in vivo and in vitro diagnostic.43
We have previously shown that intercellular adhesion mole-
cule 1 (ICAM-1)-targeted NPs could detect ICAM-1 expression 
on aortic sinus tissue sections derived from apoE-/- mice with 
a superior signal-to-noise ratio compared with immunofluores-
cence.44 Moreover, we supplemented this finding with in vivo 
data using an intradermal lipopolysaccharide challenge model in 
the ear pinna. Both fluorescence microscopy and SERS detected 
ICAM-1 expression in the ear vasculature but SERS showed 
superior sensitivity of detection.44 More recently, SERS gold 
nanorods were used for detection of adhesion molecules on 
inflamed macrophages.45 The ability to simultaneously detect 
multiple biomarkers (multiplexing) will be a key feature in early 
disease diagnosis. SERS multiplexing using five spectrally unique 
encoded NPs has been tested in vivo in mice following systemic 
administration46 with passive accumulation of non-targeted NPs 
observed in the liver at 24 hours postinjection. We are currently 
developing a SERS-based system for multiplexing detection of 
adhesion molecules ex vivo in human vascular samples and in 
vivo in mice in order to reveal early inflammatory changes in 
the vasculature (figure 1).47 Identifying the molecular signatures 
of atherosclerosis plaque in respect to multiple inflammatory 
table 2 Research supporting the use of Raman spectroscopy as a molecular imaging tool in atherosclerosis
tissue evidences species
Coronary artery  Ź Gross plaque chemical composition to quantify cholesterol, cholesterol esters, triglycerides 
and phospholipids and calcium salts
 Ź Human; samples from 16 explanted recipient hearts; 
Raman analysis on sections31
 Ź Detection of cholesterol  Ź  Human; intact artery samples32
 Ź Quantiication of relative proportions of multiple lipid classes including cholesterol, 
cholesterol esters, phospholipids and triglycerides
 Ź  Human; arterial lysates33
 Ź Detection and quantiication of elastic laminae, collagen ibres, smooth muscle cells, 
adventitial adipocytes, foam cells, necrotic core, cholesterol crystals, E-carotene containing 
crystals and calcium mineralisation using an algorithm designed to interpret Raman data
 Ź Human; samples from 16 explanted recipient hearts; 
Raman analysis on 5μm thick sections34
 Ź Relative quantiication of cholesterol, collagen and adipocyte content  Ź Human; fragments from 30 cadavers35
Brachiocephalic 
artery
 Ź Detailed Raman analysis of plaque content including lipids, remodelled media and ibrous 
cap with a spatial resolution down to 1 µM Observation of distinct protein signatures 
including haemoporphyrin and elastin
 Ź ApoE and LDLr DKO mice; transversal sections28
Aorta  Ź Measurement of endothelial dysfunction  Ź ApoE and LDLr DKO mice36
 Ź Detailed Raman analysis of lesions associated with FTIR to characterise plaque contents 
including multiple lipid classes, endothelial cells, smooth muscle cells, extracellular matrix
 Ź Hypercholesteraemic rabbit; fragments29
 Ź Quantitative mapping of chemical components  Ź ApoE mice; fragments37
 Ź Raman-probe spectroscopy to characterize the plaque composition of arterial walls  Ź Rabbit; in vivo38
Carotid artery  Ź Multimodal spectroscopic approach with the ability to detect vulnerable plaques with a 
sensitivity of 96%, speciicity of 72% and a negative predictive value of 97%
 Ź Human; endarterectomy plus femoral bypass surgery 
samples (n=12)39
 Ź Characterisation of peculiar spectral signatures related to biochemicals presented in lesion, 
eg, collagen and elastin, cholesterol and calcium hydroxyapatite
 Ź Human; fragments postmortem40
 Ź Intravascular Raman spectroscopy, using miniaturised ibre-optic probes to collect Raman 
scattered light from vessel wall
 Ź Lambs and sheep; in vivo41
 Ź Real-time in vivo collection of Raman spectra of atherosclerosis using a newly designed 
optical ibre Raman probe. Demonstration that Raman spectroscopy has capability to identify 
vulnerable plaque with 79% sensitivity and 85% speciicity
 Ź Human42
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markers could allow the interrogation of lesion staging and iden-
tify a vulnerable plaque phenotype.
therapeutic options coupled with seRs: photothermal 
apoptosis
The use of metallic NPs offers potential therapeutic applica-
tions to atherosclerosis, specifically through photothermal 
therapy in addition to acting as enhancers of Raman scattering. 
The photothermal effect arises when the plasmonic resonance 
wavelength of the NP matches the excitation wavelength of the 
laser and light is absorbed and converted to heat. If NPs are 
attached to or internalised by cells, the energy produced can 
be dissipated to the surrounding biological medium causing 
thermal destruction of the cell. Gold nanorods and single-
walled carbon nanotubes are internalised by carotid artery resi-
dent macrophages in vivo following carotid ligation in mice 
and subsequent exposure of excised ligated vessels to NIR 
excitation-induced photothermal apoptosis of the macrophage 
population.48
The first human trial using plasmonic phototherapy, as a tech-
nique for regressing atherosclerosis, was the Plasmonic Nano-
photothermal Therapy of Atherosclerosis (NANOM-FIM: 
https:// clinicaltrials. gov/ ct2/ show/ NCT01270139). This 
multicentre trial involved 180 patients aged 4565 years diag-
nosed as having coronary artery disease with flow-limiting 
lesions. The two treatment groups received either a surgical 
Figure 1 Prospective rational for surface-enhanced Raman spectroscopy (SERS) based-diagnostics for atherosclerotic inlammation. (A) 
The identiication of inlammatory biomarkers in atherosclerotic plaques may be achieved via the intravenous injection of SERS-detectable 
biofunctionalised nanoparticles into a patient. Such nanoparticles would consist of a noble metal core for surface enhancement of Raman spectra; 
a Raman reporter to provide a predetermined Raman signature; a polymer coating (such as polyethylene glycol) to reduce nanoparticle interaction 
with the immune system and prolong blood circulation time; a targeting molecule such as an antibody or aptamer to confer molecular speciicity. 
These nanoparticles would circulate in the vasculature, binding to inlammatory biomarkers such as adhesion molecules, macrophage, T-cell and 
B-cell activation markers and potentially atherosclerosis-associated biomarkers. Following binding these nanoparticles would then be detectable at 
signiicant tissue depths, eg, within the carotid artery, via surface-enhanced spatially offset Raman spectroscopy (SESORS). (B) Following the injection 
of biofunctionalised nanoparticles and the investigation of atheroprone regions of the vasculature with SESORS, detection of biomarker-speciic 
biofunctionalised nanoparticles would be recorded. Consequently, this would provide clinicians with a technology capable of detecting a panel of 
biomarkers suitable for subsequent correlation with disease severity and implementation as a potential predictor of disease outcome. A hypothetical 
example is provided whereby the detection of biofunctionalised nanoparticles indicated the presence of biomarkers A, D and E, and the absence of 
biomarkers B and C following SESORS investigation of a carotid artery. LDL, low-density lipoprotein.
 o
n
 29 M
ay 2018 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2017-311447 on 23 October 2017. Downloaded from 
465MacRitchie N, et al. Heart 2018;104:460–467. doi:10.1136/heartjnl-2017-311447
Review
implanted on-artery patch capable of transferring silica-gold 
NPs to the plaque (Nano group) or an intracoronary infusion 
of silica-gold iron-bearing NPs with CD68 targeted microbub-
bles and stem cells via a magnetic navigation system (Ferro 
group). A control group received a stent implantation void of 
any NP. Following detonation of the NPs via intravascular or 
transcutaneous NIR laser excitation, no adverse events related 
to the procedure such as site-related thrombosis were recorded 
throughout the 1-year follow-up. Both treatments were associ-
ated with a reduction in total atheroma volume and the nano 
group displayed increased survival relative to control during 
follow-up.49
Figure 2 Examples of molecular imaging strategies for atherosclerotic disease. (A) Contrast-enhanced ultrasound (CEUS) molecular imaging using 
antibody functionalised biotinylated lipid shelled decaluorobutane microbubbles (MBs) in atherosclerotic mice. Comparison of isotype control (left 
panel) and antivascular cell adhesion molecule 1 (VCAM-1) (right panel) antibody functionalised MBs demonstrates high VCAM-1 expression in the 
aortic arch. Reprinted from Kaufmann et al2, http://atvb.ahajournals.org/content/30/1/54.long (B) Spectral CT using high-density lipoproteins (HDL) 
labelled with gold has been used to image macrophage-rich plaques in apoE-/- mice. Images displayed show conventional (left panel), spectral (middle 
panel) and overlay (right panel) CT, with enrichment for gold-HDL clear in the thoracic and abdominal aorta. Reprinted from Cormode et al5, with 
permission from the Radiological Society of North America. (C) PET-CT imaging showing uptake of 18luorine functionalised with a VCAM-1 targeting 
peptide (18F-4V) in the aortic root. Wild-type mice demonstrated low signal, while atherosclerotic apoE-/- mice had signiicantly higher 18F-4V signal. 
Reprinted from Nahrendorf et al9, with permission from Elsevier. (D) Using a luorescently labelled anti-oxidised low-density lipoprotein (ox-LDL) 
antibody it was possible to image ox-LDL dense regions in atherosclerotic LDLr-/- mice. No ox-LDL signal was detected from wild-type mice. Reprinted 
from Khamis et al50, distributed under a Creative Commons CC-BY license. (E) Magnetic nanoparticles functionalised with a VCAM-1 targeting peptide 
(VINP-28) were used to image VCAM-1 using MRI. Atherosclerotic apoE-/- mice were imaged pre-VINP-28 and post-VINP-28 injection. A marked signal 
drop was observed within the aortic root wall 48 hours postinjection. The contrast-to-noise ratio of the aortic wall was increased after the probe 
injection. Reprinted from Nahrendorf et al14, http://circ.ahajournals.org/content/114/14/1504.long (F) Micro-single-photon emission tomography 
(SPECT) (top panels) and micro-SPECT-CT fusion images (bottom panels) for imaging a molecule binding to matrix metalloproteinases labelled with 
technetium-99m (Tc-MPI) in the rabbit atherosclerotic abdominal aorta, 0 and 4 hours after radiotracer administration. Reprinted from Haider et 
al
11, distributed under a Creative Commons Attribution Noncommercial License. (G) The ibrous cap of a plaque within a section of human coronary 
artery, identiied by the red arrow (left panel), has been investigated using Fourier transform infrared spectroscopy (FTIR), demonstrating the ability 
to evaluate the distribution of elastin and collagen I (red/yellow=high; blue=low concentration). Reprinted from Wetzel et al25, with permission 
from Elsevier. (H) Raman spectroscopy has been used to discriminate non-atherosclerotic tissue from atherosclerotic tissue, and also infer plaque 
phenotype, particularly with regard to calciied plaque. Shown here are Raman spectra of coronary arteries obtained ex vivo, highlighting the spectral 
differences between calciied and non-calciied atherosclerotic plaques in comparison with a non-atherosclerotic artery. Reprinted from Nogueira et 
al
40. (I) SERS spectroscopy of lipopolysaccharide-challenged ears show Raman peaks in mice with intravenous injections of anti-intercellular adhesion 
molecule 1 (ICAM-1)-conjugated nanotags (red) but no apparent spectra in mice with intravenous injections of control (IgG2b) nanotags (blue). 
Reprinted with permission from McQueenie et al44. Copyright (2012) American Chemical Society.
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Despite risks associated with induced apoptosis in the 
atheroma, this approach highlights the range of options coupled 
with SERS/NP usage. Gold NPs are also amenable as carriers 
for drug delivery to the vessel wall owing to their low toxicity, 
versatile surface chemistry conjugation and efficient uptake by 
vascular endothelial cells.47
conclusIon And outlook
Looking forward, this review has summarised activities in the 
common molecular imaging approaches in atherosclerosis, 
focusing on Raman and SERS. Images showing typical findings 
with each modality are shown in figure 2.2 5 9 11 14 25 40 44 50 The 
main area we see for advancement in the future is the devel-
opment of highly specific particle probes for use in vivo with 
IR excitation and emission profiles to allow analysis at depth 
in tissue while retaining the molecular specificity of these tech-
niques. Moreover, opportunities exist for the design of new NP 
composites, which will provide a therapeutic response including 
release of drugs. Many groups around the world appear to be 
starting to edge into this area and over the short term we expect 
there to be a large amount of visible activity and growth in this 
area coupled with some key lead examples which translate into 
clinical applications.
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